Market capitalization | $509.39m |
Enterprise Value | $958.30m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 5.53 |
P/S ratio (TTM) P/S ratio | 2.94 |
P/B ratio (TTM) P/B ratio | 1.12 |
Revenue growth (TTM) Revenue growth | 2.14% |
Revenue (TTM) Revenue | $173.15m |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
16 Analysts have issued a Pacific Biosciences of California, Inc. forecast:
16 Analysts have issued a Pacific Biosciences of California, Inc. forecast:
Sep '24 |
+/-
%
|
||
Revenue | 173 173 |
2%
2%
|
|
Gross Profit | 9.61 9.61 |
80%
80%
|
|
EBITDA | -228 -228 |
20%
20%
|
EBIT (Operating Income) EBIT | -289 -289 |
6%
6%
|
Net Profit | -394 -394 |
28%
28%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Pacific Biosciences of California, Inc. engages in the development, manufacture and sale of an integrated platform for genetic analysis. Its products and services include PacBio sequel system, consumables, analytical software, and single molecule real-time (SMRT) compatible products. It operates through the following geographical segments: North America, Europe, and Asia Pacific. The company was founded by Stephen Turner and Joseph Vincent Bonventre on July 14, 2000 and is headquartered in Menlo Park, CA.
Head office | United States |
CEO | Christian Henry |
Employees | 796 |
Founded | 2000 |
Website | www.pacb.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.